Mylan and its EpiPen manufacturing partner Pfizer have had trouble keeping up with demand. That's not good news as the key back-to-school season nears. Except, perhaps, for Novartis' Sandoz unit and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results